 |
> 2004 Publications
1.
A telomerase-immortalized primary human prostate cancer
clonal cell line with neoplastic phenotypes.
Gu Y, Kim KH, Ko D, Nakamura K, Yasunaga Y, Moul JW, Srivastava
S, Arnstein P, Rhim JS.
Int J Oncol. 2004 Oct;25(4):1057-64. 
Abstract
|
2.
Elevated expression of PCGEM1, a prostate-specific gene
with cell growth promoting function, is associated with high-risk
prostate cancer patients.
Petrovics G, Zhang W, Makarem M, Street JP, Connelly RR, Sun
L, Sesterhenn IA, Srikantan V, Moul JW and Srivastava S.
Oncogene, 23:605-611, 2004.
Abstract
| 
PDF |
3.
Eligibility and outcomes reporting guidelines for
clinical trials for patients in the state of a rising prostate-specific
antigen: Recommendations from the prostate-specific antigen
working group.
Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small
EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci
MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak
D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis
C, and Soule HR:
J Clin Oncol, 22(3):537-56, 2004.
Abstract
|
PDF |
4.
Early versus delayed hormonal therapy for prostate specific
antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda
L, Sexton W, O’Reilly K, Hernandez J, Chung A, Soderdahl
D:
J Urol, 171:1141-47, 2004.
Abstract
|
5. Race/Ethnicity and the intensity of medical monitoring
under “watchful waiting” for prostate cancer.
Shavers VL, Brown M, Klabunde CN, Potosky AL, Davis WW, Moul
JW, Fahey A:
Medical Care, 42:239-50, 2004.
Abstract
|
PDF |
6. Race/Ethnicity and the receipt of watchful waiting
for the initial management of prostate cancer.
Shavers VL, Brown M, Potosky AL, Klabunde CN, Davis WW, Moul
JW, Fahey A:
J Gen Intern Med, 19:146-55, 2004.
Abstract
|
7.
External beam radiation therapy after radical prostatectomy:
efficacy and impact on urinary continence.
Petroski RA, Warlick WB, Herring J, Donahue TF, Sun L, Smith
CV, Connelly RR, McLeod DG, Moul JW:
PCPD, 7:170-177, 2004. 
Abstract
|
PDF |
8.
Intermediate end point for prostate cancer-specific
mortality following salvage hormonal therapy for prostate-specific
antigen failure.
D’Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck
D, Renshaw AA, Loffredo M, Chen MH:
J Natl Cancer Inst, 96:509-15, 2004.
Abstract
|
PDF |
9.
The economic burden of metastatic and prostate specific
antigen progression in patients with prostate cancer: findings
from a retrospective analysis of health plan data.
Penson David F, Moul Judd W, Evans Christopher P, Doyle John
J [S], Gandhi Sanjay, Lamerato Lois:
J Urol, 171(6, Part 1 of 2):2250-2254, 2004.
Abstract
|
10.
Maximum Androgen Blockade: The debate is not closed.
Moul JW:
Rev Urol, 5(1):4-13, 2004. |
11.
Watchful Waiting and Factors Predictive of Secondary
Treatment of Localized Prostate Cancer.
Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, Lance R, Kusuda
L, Donahue T, Foley J, Chung A, Sexton W, Soderdahl D.
J Urol, Vol 171(3) March 2004 pp 1111-1116
Abstract
|
12.
Early Versus Delayed Hormonal Therapy for Prostate
Specific Antigen Only Recurrence of Prostate Cancer After
Radical Prostatectomy.
Moul JW et al:
J Urol, Vol 171(3) March 2004 pp 1141-1147
Abstract
|
13.
PSA-based biomarker for predicting mortality in prostate
cancer.
Moul JW et al:
Am J of Urol Rev, 2(6):271-277, 2004. |
14.Pathologic Variables and Recurrence Rates As Related
to Obesity and Race in Men With Prostate Cancer Undergoing Radical
Prostatectomy.
Amling, Christopher L.; Riffenburgh, Robert H.; Sun, Leon; Moul,
Judd W.; Lance, Raymond S.; Kusuda, Leo; Sexton, Wade J.; Soderdahl,
Douglas W.; Donahue, Timothy F.; Foley, John P.; Chung, Andrew
K.; McLeod, David G.:
Jour of Clin Oncology, Vol 22(3) 1 February 2004 pp 439-445
Abstract
|
15. Serum protein expression profiling for cancer detection:
validation of a SELDI-based approach for prostate cancer.
Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng
Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach RJ, McCarthy
DB, Semmes OJ, Srivastava S, Srivastava S, Thompson IM, Thornquist
MD, Verma M, Zhang Z, Zou Z.
Dis Markers. 2003-2004;19(4-5):185-95.
Abstract
|
PDF |
 Back
to Top |
|
